The clinical use of the alpha-4 integrin antagonist natalizumab may be associated with reactivation of other viruses, according to a study conducted in Ireland (Lonergan et al. J Neurovirol 2009; epublished August 9, 2009).
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with
